Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response.

@article{Goetz2008TamoxifenPT,
  title={Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response.},
  author={Matthew P. Goetz and Alsharawy Kamal and Matthew Ames},
  journal={Clinical pharmacology and therapeutics},
  year={2008},
  volume={83 1},
  pages={160-6}
}
Tamoxifen continues to be a standard endocrine therapy for the prevention and treatment of estrogen receptor (ER)-positive breast cancer. Tamoxifen can be considered a classic "pro-drug," requiring metabolic activation to elicit pharmacological activity. CYP2D6 is the rate-limiting enzyme catalyzing the conversion of tamoxifen into metabolites with significantly greater affinity for the ER and greater ability to inhibit cell proliferation. Both genetic and environmental (drug-induced) factors… CONTINUE READING
61 Citations
49 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 61 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 49 references

The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen

  • MP Goetz
  • Breast Cancer Res Treat 2007;101:113–121
  • 2007

Similar Papers

Loading similar papers…